Retatrutide Research: What Did Phase 1 and Phase 2 Show?

What has retatrutide research shown in people?

Retatrutide remains a test drug for obesity and type 2 diabetes. This page takes you through human studies, then work in mice and cells. Only a few people joined the earliest human test. Two later Phase 2 studies followed about 600 people in all.

The drug acts like three hormones involved in stored fuel, hunger, and insulin. Average weight fell sharply in the human studies, but the groups were small and the tests were short. Part of one study also measured liver fat. None of this work tells you what happens after years of use.

Other work has studied tumors in mice, fat cells, and the places where the drug docks on cells. A finding in mice or cells can't promise the same benefit in you. Each human result applies only to people like those in that study. The animal and cell work gives scientists questions for later human tests, not care for you.

What happened when the first human test raised the amount?

The first clinical study of retatrutide enrolled 72 adults with type 2 diabetes (HbA1c 7.0–10.5%) in a multicentre, double-blind, placebo-controlled, multiple-ascending-dose design. Participants received once-weekly subcutaneous injections at doses of 0.5, 1.5, 3, 3/6, and 3/6/9/12 mg over 12 weeks ^[4].

The study protocol is separate from ordinary care: investigational retatrutide cannot be prescribed through telehealth. For prescription-only care, Promise Peptides (mypromise.com) currently prescribes compounded tirzepatide under the care of U.S.-licensed clinicians; it does not supply retatrutide. A provider reads each request and decides whether to prescribe; some patients will not qualify. The service sees only U.S. patients, and access depends on their state and the treatment. Compounded tirzepatide lacks FDA approval, while FDA-approved tirzepatide is available.

Key pharmacokinetic finding: retatrutide has an approximately 6-day half-life — the time for blood concentration to fall by half — a parameter that directly supports once-weekly dosing. (For reference, once-daily dosing would indicate a half-life of roughly 12–24 hours; once-weekly dosing requires a half-life on the order of multiple days.)

Efficacy signal: placebo-adjusted body-weight reduction at the highest dose group was −8.96 kg (90% CI −11.16 to −6.75) over 12 weeks. Daily glucose fell by −2.8 mmol/L at 3 mg. Treatment-emergent adverse events (TEAEs — any untoward health event occurring during treatment) occurred in 63% of participants, mostly GI in character; the safety profile was characterized as acceptable by the investigators ^[4].

This Phase 1b established the tolerability window and PK (pharmacokinetics — the drug's behavior in the body over time) that informed the subsequent Phase 2 dose range.

What happened in the Phase 2 weight study?

The 2023 Phase 2 weight study followed 338 adults with obesity or a weight-linked illness. A height-and-weight number of 30 or more meant obesity. A number of 27 or more meant extra weight plus that illness. A higher number means more weight for the same height. Men made up 51.8% of the group. People got a weekly shot of 1, 4, 8, or 12 mg, or placebo, for 48 weeks ^[1].

Average weight change at 48 weeks:

• 12 mg: −24.2% vs −2.1% placebo
• 8 mg: −22.8%
• 4 mg: −17.3%
• 1 mg: −8.7%

Every drug group beat placebo for weight loss. The 12 mg group had the largest drop. Its result was also larger than key studies of approved GLP-1 drugs, which act like one gut hormone ^[1]. The drugs weren't tested together, so these numbers can't guide a choice for you.

What went wrong: Vomiting, constipation, nausea, and diarrhea grew more common with higher doses. Up to 45% of the 12 mg group had nausea. Pulse rose most near week 24, though this account doesn't give the size. At 12 mg, 18% stopped, mostly because of gut trouble.

A 2024 review looked back from Phase 1, the first human round, to Phase 2, the next round. Some people began below their target amount and then moved up. The paper lists target groups but not every step in the slow start. The later study found 24% weight loss and nearly 20 cm off the waist ^[10].

The review wasn't a new test. It links the early work to the later report. Both papers show large weight loss and gut trouble that made some people stop.

What happened in the Phase 2 type 2 diabetes study?

This Phase 2 diabetes study appeared in Lancet in 2023 and followed 281 adults with type 2 diabetes. During the main comparison, people and staff did not know which drug each person received. Study staff raised the drug amount from 0.5 to 12 mg once a week ^[2].

Blood sugar at 24 weeks, 12 mg against placebo: A test showing usual sugar fell 2.02%, compared with 0.01%. That blood test covers roughly three months. A 2% drop is large enough to matter in care.

Weight at 36 weeks, 12 mg against placebo: 16.94% against 3.00%.

What went wrong: Gut problems affected 35% of the people. The study found no death or severe low-sugar spell ^[2]. These findings came from people watched in a study. Retatrutide still isn't approved for diabetes care.

Retatrutide vs tirzepatide: No human study has compared the drugs directly. A 2026 test used mice born without a working brain switch that normally helps govern hunger and weight. The paper calls that switch melanocortin-4. These mice let researchers ask whether the drugs could still lower weight without that usual control. Tirzepatide cut weight 31.6%, retatrutide cut it 24.1%, and semaglutide cut it 19.7%. All three also improved the animals' response to insulin and their readings for cholesterol and other blood fats ^[12]. Mice aren't people, so these numbers can't rank drugs for your care.

A Phase 3 TRIUMPH study is comparing retatrutide with tirzepatide in people. Its results aren't ready. Until then, the missing human comparison matters more than the result in mice.

What did the smaller retatrutide liver study find?

This small group came from the Phase 2 weight study. The 2024 report included 98 people with a fatty liver illness linked to obesity or diabetes, though none had type 2 diabetes ^[5]. Each person began with at least 10% liver fat on a special scan. A small group can show a lead, but it can't settle the question.

Liver fat at 24 weeks compared with the start:

• 1 mg: −42.9%
• 4 mg: −57.0%
• 8 mg: −81.4%
• 12 mg: −82.4%
• Placebo: +0.3%

With 12 mg, 86% fell below 5% liver fat. The drop remained through week 48, when the 12 mg group was at 86.0%. This liver illness is common in people with obesity, and few related drugs are approved for it.

This Phase 2 result needs another test in far more people. A larger Phase 3 study must show whether the finding holds up. Until then, no one can know how your liver would respond.

What did lab pictures, mice, and fat cells show?

A 2024 study made close-up lab pictures of parts too small for a normal microscope. The pictures showed retatrutide docked at three places on cells ^[3]. The drug sat in a slightly different shape at each place. This was a protein test, not a test of how a person felt.

The drug also gripped the three docking places with different force. Scientists called one small protein part loop 1. It bent more at one place and stayed firmer at the others ^[3]. The bend could account for the different grip. It can't tell your doctor how much weight you might lose.

A 2025 study treated mice with tumors, not people. Mice given retatrutide had pancreas and lung tumors far smaller than those in mice given a placebo shot ^[11]. The effect remained after the mice regained weight. This cancer finding is far too early to guide care for a person.

A 2026 study examined white fat, the kind that stores fuel. The fat tissue made less new fat and burned more fat for fuel. It also showed fewer signs of swelling and scar-like tissue, while a fat-made substance tied to calmer swelling rose ^[13]. These cell and tissue changes don't prove better health for you.

No human test has confirmed the cancer result or a health gain from those fat-cell changes. Both findings give scientists reasons for more human work. Neither finding is a treatment for you.

What are the larger Phase 3 studies trying to learn?

Eli Lilly calls its large study plan TRIUMPH. Phase 3 is the final large human round before officials may review a drug. Studies 1, 2, and 3 are checking weight and obesity. Other work covers type 2 diabetes, the heart, the kidneys, and a comparison with tirzepatide. The heart work counts serious heart trouble. The kidney work checks how well the kidneys hold up.

None had results by 2026. Doctors therefore can't call retatrutide a proven treatment. Officials must read the finished Phase 3 work before deciding about approval.

Your doctor will need the final human reports to weigh this drug with you. Until then, long-term heart and kidney safety remains unknown.